RGLS - Regulus Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1900
-0.0200 (-1.65%)
As of 9:41AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.2100
Open1.2000
Bid1.1800 x 900
Ask1.2000 x 900
Day's Range1.1900 - 1.2000
52 Week Range0.8000 - 4.0800
Volume701
Avg. Volume161,801
Market Cap24.712M
Beta (3Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-3.9300
Earnings DateAug 7, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.33
Trade prices are not sourced from all markets
  • Regulus Announces New Additions to Board of Directors
    PR Newswirelast month

    Regulus Announces New Additions to Board of Directors

    Concurrently with their appointments to the Board, Mr. Nunn was appointed to serve on the Audit Committee and Dr. Simeonidis was appointed to serve on the Corporate Governance & Nominating Committee. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital.  Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity.

  • Associated Press2 months ago

    Regulus: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 31 cents per share. The biopharmaceutical company posted revenue of $6.8 million in the period. The company's shares closed at $1.25. A year ago, they ...

  • Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates
    PR Newswire2 months ago

    Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates

    "I am proud of the significant progress we have made thus far in 2019 to reposition Regulus with a strengthened balance sheet, restructured term loan and reduced operating cash burn rate.  Importantly, the team has maintained its focus in its engagement with FDA, and we look forward to resuming our ADPKD clinical program pending FDA alignment.  We believe the total potential proceeds from the recent financing, highlighted by a strong investor syndicate, provides sufficient capital to fund planned activities into the second half of 2021," said Jay Hagan, CEO of Regulus. Private Financing: In May 2019, the Company closed the first tranche of its $41.8 million private placement of equity (the "Private Placement").

  • Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity
    PR Newswire2 months ago

    Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity

    LA JOLLA, Calif. , May 7, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Therapeutics Announces Restructuring of Term Loan
    PR Newswire3 months ago

    Regulus Therapeutics Announces Restructuring of Term Loan

    LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has entered into an amendment (the "Amendment") with Oxford Finance LLC. The Amendment to the Term Loan, with a principal balance outstanding of $14.7 million, provides the Company with a new twelve-month period of interest-only payments, commencing May 2019 and a two-year extension of its maturity date to May 2022. Upon the closing of the second tranche of the Company's recently announced private financing, the Company will receive an additional twelve-month period of interest-only payments, commencing May 2020.

  • Regulus Therapeutics Announces Private Placement of Equity
    PR Newswire3 months ago

    Regulus Therapeutics Announces Private Placement of Equity

    LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors for aggregate gross proceeds of up to approximately $41.8 million in a two-tranche private placement of equity.  The initial tranche of approximately $16.7 million, priced at the market, is anticipated to close on or about May 7, 2019, subject to the satisfaction of customary closing conditions. Under the securities purchase agreement the investors have agreed to purchase, at an initial closing, approximately 9.7 million shares of the Company's Common Stock ("Common Stock") and accompanying warrants to purchase up to an aggregate of approximately 9.7 million shares of Common Stock, at a combined purchase price of $1.205 per share and accompanying warrant.

  • Will Regulus (RGLS) Report Negative Q1 Earnings? What You Should Know
    Zacks3 months ago

    Will Regulus (RGLS) Report Negative Q1 Earnings? What You Should Know

    Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress™ 2019
    PR Newswire3 months ago

    Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress™ 2019

    "We are pleased to be presenting preclinical data during this year's EASL International Liver Congress that we believe demonstrates the potential of our lead anti-miR-132 to be a promising therapeutic for the treatment of NASH," said Jay Hagan, President and Chief Executive Officer of Regulus. Details of the late breaker poster presentation are as follows and will be available for download at the time of presentation at http://regulusrx.com/publications.

  • ACCESSWIRE4 months ago

    Four Healthcare Stocks Getting a Boost on Thursday

    CORAL GABLES, FL / ACCESSWIRE / March 28, 2019 / The healthcare stock market has been a hotbed of excitement in the first few months of 2019 as companies in the industry have focused their efforts on developing innovative technologies and treatments for consumers. Consumers depend and expect healthcare companies to invest in new forms of drug treatments and other aspects of the care experience so that, when a patient needs care, they don't have to look very far. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Arcturus Therapeutics Ltd (ARCT), Sesen Bio Inc (SESN), and Regulus Therapeutics Inc (RGLS) are 4 healthcare companies making moves on Thursday.

  • Associated Press4 months ago

    Regulus: 4Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 98 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates
    PR Newswire4 months ago

    Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates

    LA JOLLA, Calif. , March 18, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Announces Transition of Research Leadership
    PR Newswire4 months ago

    Regulus Announces Transition of Research Leadership

    LA JOLLA, Calif., March 15, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the resignation of Dr. Timothy Wright, Chief Research and Development Officer, effective March 15, 2019.  Dr. Wright is leaving for personal reasons to pursue a new opportunity, and will continue to support Regulus as a scientific advisor.

  • Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme
    PR Newswire6 months ago

    Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme

    Standard of care temozolomide as a single agent increased median survival by 27% vs. control, therefore the combination of RGLS5579 plus temozolomide demonstrated synergistic efficacy in this model. RGLS5579 has completed the clinical candidate screening process demonstrating appropriate preliminary safety and drug-like properties.

  • Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study
    PR Newswire7 months ago

    Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study

    LA JOLLA, Calif., Jan. 4, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the preliminary results of a planned interim data analysis from the new mouse chronic toxicity study of RGLS4326 in development for the treatment of Autosomal Dominant Polycystic Kidney Disease, or ADPKD. As previously reported by the Company in July 2018, and in consultation with FDA, the Company voluntarily paused its ongoing Phase 1 Multiple Ascending Dose ("MAD") study of RGLS4326 in healthy volunteers due to unexpected observations in the 27-week mouse chronic toxicity study.  The Company terminated that mouse study prematurely at week 14.  The study was run in parallel to the Phase 1 program to enable initiation of the Phase 2 program in ADPKD patients upon completion of the Phase 1 MAD study.

  • Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares
    Simply Wall St.7 months ago

    Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...

  • GlobeNewswire8 months ago

    Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme
    PR Newswire8 months ago

    Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme

    Single Dose of Lead anti-miR-10b Compound in Combination with temozolomide Resulted in over 150% Increase in Median Survival LA JOLLA, Calif. , Nov. 19, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . ...

  • Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
    Zacks8 months ago

    Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

    Regulus (RGLS) delivered earnings and revenue surprises of 24.36% and -10.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press8 months ago

    Regulus: 3Q Earnings Snapshot

    The San Diego-based company said it had a loss of $1.18 per share. The biopharmaceutical company posted revenue of $18,000 in the period. In the final minutes of trading on Thursday, the company's shares ...

  • Regulus Reports Third Quarter 2018 Financial Results and Recent Updates
    PR Newswire8 months ago

    Regulus Reports Third Quarter 2018 Financial Results and Recent Updates

    $47 Million Restructured Sanofi Collaboration Executed Initiated New Chronic Mouse Toxicity Study for RGLS4326; Data Anticipated in Q1 2019 LA JOLLA, Calif. , Nov. 8, 2018 /PRNewswire/ --  Regulus Therapeutics ...

  • Regulus Announces Successful Restructuring of Sanofi Collaboration
    PR Newswire8 months ago

    Regulus Announces Successful Restructuring of Sanofi Collaboration

    Sanofi Will Assume Development of RG-012 for Alport syndrome LA JOLLA, Calif. , Nov. 6, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery ...

  • Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018
    PR Newswire9 months ago

    Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018

    LA JOLLA, Calif. , Oct. 25, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • ACCESSWIRE9 months ago

    3 Healthcare Stocks To Watch On Tuesday

    Healthcare stocks have helped during times like these. Three healthcare stocks to watch this week include Premier Health Group, Inc. (PHGRF)(PHGI.CN), Neovasc Inc. (NVCN), and Regulus Therapeutics Inc. (RGLS). Premier Health Group, Inc. (PHGRF)(PHGI.CN), continued to trade higher this week.

  • Benzinga9 months ago

    The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks None of the stocks hit 52-week highs in Monday's session. Down In The Dumps (Biotech stocks hitting 52-week ...

  • Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018
    PR Newswire9 months ago

    Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018

    LA JOLLA, Calif. , Oct. 22, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...